4-1BB (2)

Immunotherapy, cancer research, drug screening

Humanized Strategy

Validation Data

Figure 1. Expression of humanized CD137 (4-1BB) in the activated spleen lymphocytes of heterozygous humanized 4-1BB mice is detected by FACS.

The spleen lymphocytes of heterozygous humanized 4-1BB mice were activated by anti-CD3 and anti-CD28 for 48 hours, and then collected for staining. The expression of humanized 4-1BB was detected by FACS. The results showed that the active expression of humanized 4-1BB can be detected in both activated CD4+ and CD8+ T lymphocytes collected from heterozygous humanized 4-1BB mice.

(Data in partnership with collaborators)

Figure 2. Analysis of human 4-1BB (CD137) expression in the spleen by FACS. The homozygous KI mouse expresses human 4-1BB on the CD8+ T cells.

Figure 3. In vivo validation of humanized 4-1BB mice. Humanized 4-1BB mice were inoculated with MC38 colon cancer cells, and were randomly assigned into different groups (n=6) when the tumors grew to a volume of 100 mm3. Human-specific, 4-1BB antibody ( Urelumab or Utomilumab) was given every three days (Q3D) for two weeks.

(Data in partnership with collaborators)